Curasight A/S ("Curasight" or "the Company" – TICKER: CURAS), a clinical-stage radiopharmaceutical company developing first-in-class drug candidate uTREAT® targeting uPAR (urokinase-type plasminogen ...
A new analysis supports the use of intravenous (IV) tenecteplase over IV alteplase (tissue plasminogen activator) for treatment of acute ischemic stroke. The analysis found that patients with ischemic ...
More than 30% of patients with pleural infection either die or require surgery. Drainage of infected fluid is key to successful treatment, but intrapleural fibrinolytic therapy did not improve ...
Clinical Relevance of Invasion Factors Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1 for Individualized Therapy Decisions in Primary Breast Cancer Is Greatest When ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback